ADPN

Metabolic syndrome (MetS) is a pathological condition characterized by abdominal obesity, insulin resistance, hypertension, and hyperlipidemia, affecting at least 35% of the U.S. population. Cardiovascular diseases are among the most severe comorbidities, significantly increasing MetS-related mortality. Understanding the pathophysiology of MetS is crucial for developing novel diagnostic and therapeutic strategies. Circulatory adiponectin levels are implicated in MetS, as this pleiotropic hormone exerts antioxidative, anti-nitrative, anti-inflammatory, and cardioprotective effects. Investigating tissue-specific adiponectin signaling pathways may help identify targeted interventions to mitigate MetS and its complications. This review explores the role of adiponectin as a potential biomarker and therapeutic target, offering insights into its mechanistic contributions to MetS pathophysiology.